| Literature DB >> 25526513 |
Cuilian Ye1, Weiwei Yan2, Hua Xiang3, Hongxuan He4, Maosheng Yang5, Muhammad Ijaz2, Nicodemus Useh2, Ching-Lin Hsieh2, Patrick L McDonough2, Sean P McDonough6, Hussni Mohamed2, Zhibang Yang7, Yung-Fu Chang2.
Abstract
Animal leptospirosis is one of the most common zoonotic diseases in the United States and around the world. In a previous study, we applied four recombinant antigens, rLipL21, rLoa22, rLipL32 and rLigACon4-8 of Leptospira interrogans (L. interrogans) for the serological diagnosis of equine leptospirosis (Ye et al, Serodiagnosis of equine leptospirosis by ELISA using four recombinant protein markers, Clin. Vaccine. Immunol. 21:478-483). In this study, the same four recombinant antigens were evaluated for their potential to diagnose canine leptospirosis by ELISA. A total of 305 canine sera that were Leptospira microscopic agglutination test (MAT)-negative (n = 102) and MAT-positive (n = 203) to 5 serovars (Pomona, Grippotyphosa, Icterohaemorrhagiae, Canicola and Hardjo) were tested. When individual recombinant antigens were used, the sensitivity and specificity of ELISA were 97.5% and 84.3% for rLigACon4-8; 89.7% and 81.4% for rLoa22; 92.6% and 84.3% for rLipL32 and 99.5% and 84.3% for rLipL21, respectively compared to the MAT. The sensitivity and specificity of ELISA were, 92.6% and 91.2% for rLigACon4-8 and rLipL32, 97.5% and 84.3% for rLigACon4-8 and rLipL21, 89.7% and 87.3% for rLigACon4-8 and rLoa22, 89.7% and 87.3% to rLipL21 and rLoa22, 92.6% and 91.2% for rLipL21 and rLipL32 and 89.2% and 94.1% for rLoa22 and rLipL32 when one of the two antigens was test positive. The use of all four antigens in the ELISA assay was found to be sensitive and specific, easy to perform, and agreed with the results of the standard Leptospira Microscopic Agglutination test (MAT) for the diagnosis of canine leptospirosis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25526513 PMCID: PMC4272274 DOI: 10.1371/journal.pone.0111367
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Graph of the ELISA samples showing the IgG ELISA reactivity of 305 canine sera.
The x axis indicates the MAT titers of the tested sera. The y axis indicates the ELISA reading at OD450. A. LipL21; B. Loa22; C, LipL32; D, LigACon4-8.
MAT, ELISA and Western blot analysis of the serum sample used in this study.
| protein name | MAT- | MAT+ | ||||
| MAT- serum number | MAT- & ELISA- | MAT- & ELISA- & WESTERN- | MAT+ serum number | MAT+ & ELISA+ | MAT+ & ELISA+ & WESTERN+ | |
| rLipL21 | 102 | 86 | 80 | 203 | 202 | 168 |
| rLoa22 | 102 | 83 | 59 | 203 | 182 | 127 |
| rLipL32 | 102 | 86 | 70 | 203 | 188 | 146 |
| rLigACon4-8 | 102 | 86 | 68 | 203 | 198 | 130 |
Sensitivity and specificity of the ELISA test when a single protein was evaluated in comparison to the MAT result.
| sensitivity | specificity | |
| rLipL21 | 99.5% | 84.3% |
| rLoa22 | 89.7% | 81.4% |
| rLipL32 | 92.6% | 84.3% |
| rLigACon4-8 | 97.5% | 84.3% |
Sensitivity and specificity of the ELISA test.
| proteins | a | b | c | d | Sensitivity | Specificity |
| L21&L22 | 182 | 21 | 13 | 89 | 89.7% | 87.3% |
| L21&L32 | 188 | 15 | 9 | 93 | 92.6% | 91.2% |
| L21&LigA | 198 | 5 | 16 | 86 | 97.5% | 84.3% |
| L22&L32 | 181 | 22 | 6 | 96 | 89.2% | 94.1% |
| L22&LigA | 182 | 21 | 13 | 89 | 89.7% | 87.3% |
| L32&LigA | 188 | 15 | 9 | 93 | 92.6% | 91.2% |
| L21&L22&L32 | 181 | 22 | 6 | 96 | 89.2% | 94.1% |
| L21&L22&LigA | 182 | 21 | 13 | 89 | 89.7% | 87.3% |
| L21&L32&LigA | 188 | 15 | 9 | 93 | 92.6% | 91.2% |
| L22&L32&LigA | 181 | 22 | 6 | 96 | 89.2% | 94.1% |
| L21&L22&L32&LigA | 181 | 22 | 6 | 96 | 89.2% | 94.1% |
When all two, three or four of these recombinant proteins were tested positive, the serum sample was judged to be positive. Otherwise, it was judged to be negative.
*a: MAT+&ELISA+; b: MAT+&ELISA-; c: MAT-&ELISA+; d:MAT-&ELISA-;
Sensitivity = a/(a+b); specificity = d/(c+d).
Sensitivity and specificity of the ELISA test.
| proteins | a | b | c | d | Sensitivity | Specificity |
| L21&L22 | 202 | 1 | 22 | 80 | 99.5% | 78.4% |
| L21&L32 | 202 | 1 | 23 | 79 | 99.5% | 77.5% |
| L21&LigA | 202 | 1 | 16 | 86 | 99.5% | 84.3% |
| L22&L32 | 189 | 14 | 29 | 73 | 93.1% | 71.6% |
| L22&LigA | 198 | 5 | 22 | 80 | 97.5% | 78.4% |
| L32&LigA | 198 | 5 | 23 | 79 | 97.5% | 77.5% |
| L21&L22&L32 | 202 | 1 | 29 | 73 | 99.5% | 71.6% |
| L21&L22&LigA | 202 | 1 | 22 | 80 | 99.5% | 78.4% |
| L21&L32&LigA | 202 | 1 | 23 | 79 | 99.5% | 77.5% |
| L22&L32&LigA | 198 | 5 | 29 | 73 | 97.5% | 71.6% |
| L21&L22&L32&LigA | 202 | 1 | 29 | 73 | 99.5% | 71.6% |
When one of the two, three or four proteins was positive in the ELISA test in comparison to the MAT test, the serum was considered positive.
*a: MAT+&ELISA+; b: MAT+&ELISA-; c: MAT-&ELISA+; d:MAT-&ELISA-;
Sensitivity = a/(a+b); specificity = d/(c+d).
Figure 2Western blot analysis of canine serum.
Sera that were MAT negative but ELISA positive (A) and MAT positive, but ELISA negative (B) were further tested by Western blotting. Purified recombinant proteins rLipL21, rLoa22, rLipL32 and rLigACon4-8 of L. interrogans were transferred from the SDS-PAGE separation gel to a nitrocellulose membrane. After washing with TBS, the membranes were blocked and then subjected to assay using the serum to be tested as the primary antibody and l∶3,000-diluted, alkaline phosphatase-labeled goat anti-dog IgG (KPL, Inc., MD) as the secondary antibody. After this, the membranes were incubated in freshly prepared BCIP-NBT color development solution (Invitrogen) for 10 to 30 min to see the results. The number is the dog serum number that was ELISA positive.
Comparison of MAT negative and ELISA and Western blot analysis positive or MAT positive, but ELISA and Western blot analysis negative.
| MAT- | MAT+ | |||
| Protein name | ELISA+ | ELISA+ &WESTERN+ | ELISA- | ELISA- &WESTERN- |
| rLipL21 | 16 | 13 | 1 | 1 |
| rLoa22 | 19 | 14 | 21 | 15 |
| rLipL32 | 16 | 12 | 15 | 12 |
| rLigACon4-8 | 16 | 12 | 5 | 3 |
The ELISA and Western blot analysis of the 29 samples that were MAT negative, but ELISA positive to one to four of these antigens.
| Serum # | Lip21L | Loa22L | Lip32L | LipACon4-8 |
| 1 | +/+ | −/+ | +/+ | +/+ |
| 2 | +/+ | −/+ | +/+ | +/+ |
| 3 | −/− | −/− | +/+ | −/− |
| 4 | −/− | −/− | +/− | −/− |
| 5 | −/− | −/− | +/− | −/− |
| 6 | −/− | −/− | +/+ | −/− |
| 7 | −/− | −/− | +/+ | −/− |
| 8 | −/− | −/− | +/− | −/− |
| 9 | −/− | −/− | +/− | −/− |
| 10 | −/− | +/+ | −/− | −/− |
| 11 | +/+ | +/+ | −/− | +/+ |
| 12 | +/− | +/+ | −/− | +/− |
| 13 | +/+ | +/+ | −/− | +/− |
| 14 | +/+ | +/+ | −/− | +/+ |
| 15 | +/− | +/− | −/− | +/− |
| 16 | +/+ | +/+ | −/− | +/+ |
| 17 | −/− | +/− | −/− | −/− |
| 18 | +/− | +/+ | −/− | +/− |
| 19 | +/+ | +/+ | +/+ | +/+ |
| 20 | +/+ | +/+ | +/+ | +/+ |
| 21 | +/+ | +/+ | +/+ | +/+ |
| 22 | +/+ | +/+ | +/+ | +/+ |
| 23 | +/+ | +/+ | +/+ | +/+ |
| 24 | +/+ | +/+ | +/+ | +/+ |
| 25 | −/− | +/− | −/− | −/− |
| 26 | −/− | +/+ | −/− | −/− |
| 27 | −/− | +/− | −/− | −/− |
| 28 | +/+ | −/− | +/+ | +/+ |
| 29 | −/− | +/− | −/− | −/− |
* ELISA/WB: -, negative; + is positive.
The ELISA and Western blot analysis of the 22 samples that were MAT positive, but ELISA negative to at least one to four of these antigens.
| Serum # | Lip21L | Loa22L | Lip32L | LipACon4-8 |
| 1 | +/+ | −/− | −/− | +/+ |
| 2 | +/+ | −/+ | +/+ | +/+ |
| 3 | −/− | −/− | −/− | −/− |
| 4 | +/− | −/− | −/− | +/− |
| 5 | +/− | −/− | −/− | +/− |
| 6 | +/− | −/− | −/− | +/− |
| 7 | +/+ | −/+ | +/+ | +/+ |
| 8 | +/− | −/− | −/− | −/+ |
| 9 | +/− | −/− | −/− | +/+ |
| 10 | +/− | −/− | −/− | +/− |
| 11 | +/+ | −/− | +/+ | +/+ |
| 12 | +/+ | −/− | −/+ | +/+ |
| 13 | +/+ | −/− | −/− | +/− |
| 14 | +/+ | −/+ | +/+ | +/+ |
| 15 | +/+ | +/+ | −/+ | +/+ |
| 16 | +/+ | −/− | −/− | −/− |
| 17 | +/+ | −/− | −/− | −/+ |
| 18 | +/+ | −/− | +/+ | +/+ |
| 19 | +/+ | −/− | −/− | −/− |
| 20 | +/+ | −/+ | −/+ | +/+ |
| 21 | +/+ | −/+ | +/+ | +/+ |
| 22 | +/+ | −/+ | +/+ | +/+ |
* ELISA/WB: -, negative; + is positive.